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Abstract
Cardiogenic shock (CS) still remains a leading cause of hospital death. The adoption of
percutaneous ventricular assist devices (pVADs) as treatment of CS is an option which
continues to rise. Several types of pVADs have been developed by time to provide full
cardiac support with few related complications and easy implantation settings. pVADs
are used to support the failing heart as a bridge to recovery, decision, durable device or
heart transplantation. None of these devices adopted in the clinical practice is ideal for all
patients. Disadvantages may be related to the risk of limb/arm ischaemia or cerebral
stroke or haemolysis. The most important choice is to identify the best device for each
patient depending on haemodynamics, clinical scenario and patient anatomical/patholog-
ical issues. This chapter discusses the current pVAD options to treat CS patients.
Keywords: pVADs, IABP, ECMO, cardiogenic shock, refractory end-stage heart failure,
bridge-to-bridge therapy
1. Introduction
Cardiogenic shock (CS) still remains a leading cause of hospital death [1–5]. So far the most
common cause of CS is myocardial infarction. However, acute regurgitant valve failure, myo-
carditis, post-cardiotomy shock and acute on chronic heart failure also may present with end-
organ dysfunction from hypoperfusion due to cardiac pump failure, the hallmark of this
syndrome. The adoption of percutaneous ventricular assist devices (pVADs) as treatment of
CS is an option which continues to rise [1–5]. Several types of pVADs have been developed by
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time to provide full cardiac support with few related complications and easy implantation
settings. There are only few randomized trials on pVADs, and the current use of them depends
on single centre experience [1–5]. pVADs are used to support the failing heart as a bridge to
recovery, decision, durable device or heart transplantation (Htx). Improvement in haemo-
dynamic parameters by pVADs has clearly been demonstrated though without mortality
benefit in the limited studies to date [1–5]. Early versus late implementation of support may
prevent or ameliorate systemic inflammation and end-organ dysfunction in CS syndrome [1–5].
None of these devices used in the clinical practice is ideal for all patients. Disadvantages may
be related to the risk of limb/arm ischaemia or cerebral stroke or haemolysis [1–5]. The most
important choice is to identify the best device for each patient depending on haemodynamics,
clinical scenario and patient anatomical/pathological issues.
This chapter discusses the current pVAD options to treat CS patients.
2. Intra-aortic balloon pump
The intra-aortic balloon pump (IABP) device has been available since 1968 [1–5], and it remains
the most used pVAD in clinical practice. It consists of a cylindrical polyethylene balloon that is
inserted through the femoral artery and placed into proximal descending aorta distal to the
Device IABP TandemHeart Impella 2.5 Impella CP Impella 5.0 Peripheral
ECMO
Cannula size 7.9 Fr 21 Fr inflow;
15–17 Fr outflow
13 Fr 14 Fr 22 Fr Centrifugal
Pump
mechanism





















































4 L/min 2.5 L/min 3.7 L/min 5.0 L/min >4.5 L/min
Implantation
time
+ +++ ++ ++ ++++ ++
Risk of leg (or
arm) ischaemia
+ +++ ++ ++ ++ +++
Anticoagulation + +++ + + + +++
Table 1. Comparison of percutaneous support devices [1–5].
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subclavian artery. The balloon inflates during diastole and increases the perfusion of coronary
arteries via retrograde flow. The antegrade displacement of the blood caused by the inflation of
the balloon increases the mean arterial pressure (MAP) and the flow to the body. The onset of
ventricular systole leads to a rapid deflation of the balloon with the drop of the pressure in the
aorta and consequently the forward flow with a reduction in afterload, left ventricular end-
diastolic pressure (LVEDP) and rise in stroke volume and cardiac output. The decrease of left
ventricular wall tension, coronary microvascular resistance and LVEDP along with the rise of
diastolic pressure reduces the oxygen consumption and therefore myocardial ischaemia [1–5].
It usually provides a marginal increase in cardiac output of up to 0.5 l/min (Table 1). The
placement of the device is quite easy to perform. A radiopaque tip is inserted through the
arterial access and placed under fluoroscopy, confirmed by the use of the X-ray. To be effective,
it requires some level of left ventricular function of the patient and stable electrical rhythm. It
should not be used in patients with more than mild aortic insufficiency because of the eventual
increase of the diastolic retrograde flow. There are several potential complications due to the
IABP placement like balloon rupture, leak or entrapment, infection, limb ischaemia and cere-
bral stroke. Rarely, it may be the cause of aortic dissection or rupture. The use of the IABP has
been tested in several studies [6–9]. The SHOCK trial demonstrated a decrease of hospital
mortality in patients with myocardial infarction associated with the thrombolytic therapy or
early interventional/surgical revascularization [6, 7]. Nevertheless, there is an increased risk of
complications like stroke and bleeding and no improvement in mortality in several meta-
analyses when IABP is used for CS due to myocardial infarction [6, 7]. In spite of this, IABP
use is widely common and has Class II indications in the current guidelines [8].
3. TandemHeart
The TandemHeart (CardiacAssist, Inc., Pittsburgh, PA) is a continuous-flow centrifugal assist
device that was first studied by Thiele et al. [1–5, 9, 10] who randomized 41 patients with CS
after acute myocardial infarction (AMI) to IABP or TandemHeart and showed an improvement
in cardiac output, power index, pulmonary capillary wedge pressure and mean pulmonary
arterial pressure in the second group. On the other side, there was an increased risk of limb
ischaemia and coagulopathy [9, 10]. TandemHeart transfers oxygenated blood from the left
atrium to the iliac arteries and perfuses the aorta retrogradely [1–5, 9–12]. It provides up to 5 L
of haemodynamic support (Table 1). One cannula is introduced through the femoral vein up to
the right atrium and by means of a transseptal puncture to the left atrium (Figure 1). Hence,
the oxygenated blood from the left atrium is directed to the pump, and by means of a second
cannula into the femoral artery, it can be delivered to the body. It requires very good expertise
in transseptal puncture. Contraindications are aortic insufficiency, peripheral vascular dis-
eases, the presence of thrombus in the right and left atrium and coagulopathy. The possible
dangerous complications due to the placement of the device are cardiac perforation and
tamponade, infection and embolic events including limb ischaemia and cerebral stroke. The
TandemHeart device is approved for up to 6 hours of extracorporeal support for cardiopulmo-
nary bypass [1–4, 9–12]. The placement of the device requires between 30 and 45 minutes with
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full systemic heparinization [1–4, 9–12]. The left ventricle preload, the filling pressures and the
wall stress are reduced, and the peripheral tissue perfusion is increased. Several studies demon-
strate a better support and improved haemodynamics than the IABP, but themortality benefit is
the same [9–12]. The Texas Heart Institute experience analyzed 117 patients with severe CS
refractory to pharmacological therapy and/or IABP and found a significant improvement in
cardiac index and systolic blood pressure [11, 12]. In the 2015 Guidelines for Heart failure, the
TandemHeart may be considered in severe left ventricle dysfunction or recent decompensated
heart failure with associated technically challenging or prolonged percutaneous intervention
(PCI) and continued deterioration of CS patient despite IABP and/or Impella [8].
4. Impella
The Impella Recover LP (Abiomed Inc., Danvers, MA) is a microaxial pump that moves the
blood continuously from the LV to the ascending aorta [1–5] (Figure 2). There are three classes
(Table 1) currently available—the Impella 2.5, Impella CP and Impella 5.0—depending on the
level of LV support (2.5, 3.5 and 5 L/min, respectively). The Impella 2.5 and CP are the most
commonly used [1–5]. The system is composed of three major components: catheter, purge
system and automated controller. An impeller and the adjacent motor are positioned near the
outlet area in the ascending aorta. Thanks to the rotation, the negative pressure draws the
ventricular blood into the inlet area and through the cannula. The Impella 2.5 is used for up to
6 hours for high-risk PCI to prevent haemodynamic instability, while the CP model is indicated
for up to 6 hours for partial circulatory support when the cardiopulmonary bypass is not
required. Like the TandemHeart, the Impella devices have superior haemodynamics if com-
pared to the IABP in patients with ischaemic cardiogenic shock [1–5]. The Impella 5.0 was
developed initially for femoral artery, but nowadays it is positioned through the axillary or
subclavian artery. There are two clinical effects provided by this device: the unloading of the
cardiac ventricle and the increase in forward flow. The left ventricle wall tension and the
Figure 1. TandemHeart inflow cannula across the atrial septum.
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myocardial oxygen demand are decreased. There is also evidence of improved coronary perfu-
sion pressure and decrease of microvascular resistances [1–5]. The most important limitation of
Impella adoption is the size of peripheral vessels to accommodate the large bore catheters.
Anticoagulation is required, so the presence of coagulopathy or recent hemorrhage may pro-
hibit the use of this device. Other contraindications to the use of Impella are the presence of a
mechanical aortic valve prosthesis or a left ventricle (LV) mural thrombus. The improper
positioning or inadequate LV volume may cause suction. Hence, the correct Impella position
has to be confirmed with imaging. Case studies [1–5, 13–15] demonstrated successful use of the
Impella 5.0 as bridge from ECMO to durable device, during acute rejection in Htx, LV support
in RV failure as bridge to durable left ventricular assist device (LVAD), bridge to recovery in
patients with myocarditis and bridge to heart transplantation. There are several potential
complications due to the use of this device. They include bleeding, infection, vascular injury,
stroke, haemolysis, cardiac tamponade and damage to the aortic valve. The PROTECT II trial
randomized 452 symptomatic patients with complex multivessel disease or unprotected left
main disease and severely depressed LV function, thus showing the superiority of IMPELLA
compared with the IABP support [13–15]. Additionally, the catheter-based ventricular assist
device (cVAD) registry, which is an observational, multicentre, retrospective registry of patients
supported with Impella, reflects the device real-world use and suggests greater survival with
pre-PCI Impella insertion than pre-PCI IABP and/or pharmacotherapy alone [13–15].
Figure 2. Impella recover left ventricular support.
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5. Extracorporeal membrane oxygenation
Extracorporeal membrane oxygenation (ECMO), as being a heparin-coated closed circuit, is a
model of mechanical pulmonary or cardiopulmonary support that can be used for a prolonged
period [1–5, 16–20]. There are two types of ECMO support: venovenous (VV) and venoarterial
(VA). The first one provides only respiratory support since the blood is taken from the right
atrium and then oxygenated and CO2 removed prior to being returned to the right atrium.
Both the inflow and the outflow cannulae are positioned through a venous access. It works
only for gas exchange in a respiratory failure clinical scenario. The exception is when the
outflow cannula is placed in the pulmonary artery to unload and support the right ventricle
(RV). In contrast, the VA ECMO provides both haemodynamic/cardiac and respiratory sup-
ports. It is used during left ventricular or biventricular failure. The inflow cannula is placed
into the right atrium or inferior vena cava, and the blood after gas exchange is delivered back
into the arterial vascular system at either peripheral or central cannulation sites. It can provide
flows up to 6 L/min without any intrinsic activity of the heart (Table 1). The components of
ECMO system are drainage and perfusion cannulae, centrifugal or roller pump, membrane
oxygenator and heart exchanger. ECMO is important in the case of the need of haemodynamic
support for patients with CS or requiring a salvage treatment while on cardiac arrest. It
decreases the preload of both right and left ventricles, increases the mean arterial pressure
(MAP) and improves end-organ perfusion. Since it increases the LV afterload, the myocardial
oxygen consumption is not reduced. The amount of flow depends on the size of the cannulae
and the speed of the pump. Even ECMO requires full systemic heparinization [1–5, 16–19].
Contraindications are the presence of an irreversible clinical process, severe multiple organ
failure, aortic dissection, peripheral arterial disease and aortic regurgitation. Potential compli-
cations are bleeding, injury of vascular vessels, limb or arm ischaemia and thromboembolic
events. There are no large randomized trials on the use of ECMO. The Extracorporeal Life
Support Organization (ELSO) registry demonstrated a 27% survival to hospital discharge [16,
20]. Recently, a 49% survival was reached with the use of other types of mechanical support
systems plus ECMO in a bridge-to-bridge setting as treatment of CS [1–5, 16–20]. Current
guidelines recommend the use of ECMO when concomitant hypoxaemia and RV failure are
present [1–5, 8, 16–20].
6. Right ventricular assist devices
For several decades the volume administration to maintain RV preload, the vasodilators to
decrease RV afterload and the inotropes to ameliorate RV contractility have been used in
clinical practice [1–5, 21–27]. The in-hospital mortality is high in patients with RV failure that
is refractory to maximal medical treatment [1–5, 21–27]. With the TandemHeart, the percuta-
neous right ventricular assist device (RVAD) support has become a reality [21]. The
TandemHeart is used to provide RV support in such conditions as RV infarction and severe
pulmonary hypertension and temporary RV support after placement of a long-term LVAD. In
this version the TandemHeart cannulae are positioned into the right atrium and the pulmonary
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artery [21]. One model of Impella device, the RP, is approved by the Food and Drug Admin-
istration (FDA) for humanitarian device exemption for patients who develop acute right heart
failure or decompensation after LVAD implantation, AMI and Htx [22]. The device is
implanted into the femoral vein for inflow through the inferior vena cava to reach the outlet
area in the pulmonary artery (Figure 3). The RECOVER RIGHT trial was a prospective
multicentre study that was conducted in 2014 to evaluate the safety and efficacy of the Impella
RP [22]. There was successful implantation in 90% of patients who suffered from RV failure
with an increase of cardiac index and 73% successful survival to either 30 days or to hospital
discharge [22]. Contraindications to the use of this device include severe regurgitation, stenosis
or replacement of the tricuspid or pulmonic valves, the presence of filter in the inferior vena
cava or the presence of thrombus in the right atrium or in the inferior vena cava. Possible
complications are tamponade, vascular injury, liver failure, injury to the tricuspid and pul-
monic valves. The other extracorporeal devices used in the clinical practice are the Levitronix
CentriMag (Abbott), currently, while the Rotaflow (Maquet) and the Abiomed AB 5000
(Abiomed), historically [23–27]. It is important to choose the adequate sizing for inflow and
Figure 3. Impella RP setting.
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outflow cannulae to achieve the proper venous drainage and maintain a flow up to 7–8 L/min.
Several approaches for RVAD circuit setting arrangement exist nowadays [23–27]. The stan-
dard approach requires a full median sternotomy. The inflow cannula is positioned in the right
atrium and the outflow in the main pulmonary artery, both secured by double purse-string
sutures. The explantation of the device, at the time of RV recovery, requires a re-sternotomy
approach. Additionally, alternative effective minimally invasive approaches for RVAD place-
ment exist [23–27]. The one reported by Cohn et al. [25] needs vessel grafts with bedside removal
because the cannulas are inserted from outside the chest of the patient and reach the right atrium
and the pulmonary artery through the attached grafts. The grafts are firmly secured around their
cannulas with heavy sutures. When RV support is no more necessary, the pump lines are
clamped, the redundant portions from inside are exposed, the tapes are cut and the cannulas
removed, without reopening the chest [25]. A modified transcutaneous technique has been
described by Strauch et al. [26]. A minithoracotomy approach may be used in the case of post-
LVAD RV failure [23, 24] (Figure 4). According to this Berlin technique, the main pulmonary
artery cannula is located through a transthoracic needle under transesophageal echo (TEE)
guidance. The venous cannula of RVAD is advanced through the inferior vena cava into the
right atrium by Seldinger approach. This technique is difficult in the case of severe adhesions
related to previous cardiothoracic surgery [23, 24].
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